ProteoMonitor GenomeWeb News Premium Content Existing subscribers login here. New to ProteoMonitor? For a trial subscription click here.

One Year After Acquisition, Caprion
Still Eyes Sale to Rx — But No Rush

[July 31, 2008]

By Tony Fong

A year after saying Caprion Proteomics’ purchase by a hedge fund was positioning it for a bigger payout, the company’s chief executive this week said that the firm’s plan to be bought by a drug maker remains on course, but because of strength in its biomarker-discovery and -validation service business the firm will take its time finding a suitor.

Login | Subscribe